Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
NHS availability is unlikely before the mid-to-late 2020s at the earliest, as retatrutide must first complete phase 3 trials, receive MHRA marketing authorisation, and undergo a NICE health technology appraisal to assess its clinical and cost-effectiveness
In the UK, GHK-Cu products are sold as cosmetics regulated under GB Cosmetic Products Regulation and cannot legally make medicinal claims about treating hair loss
Batch documentation Batch-specific analytical documentation supports receiving, verification, and internal recordkeeping
Pooled estimates were calculated using two approaches: (i) weighted mean baseline weight with 95% confidence intervals, weighting each arm by sample size
US$ 23.90
US$ 27.39
US$ 27.31
US$ 21.63
US$ 25.25
US$ 23.23
US$ 26.31
US$ 22.15
US$ 22.54
US$ 23.27
US$ 28.82
